Managing Editor – Europe
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Tom Gallen
Italy's Recordati enjoyed strong growth in its home market and abroad, lifting OTC group sales in 2019.
Countries across Europe are restricting sales of OTC drugs in response to COVID-19 to maintain supply and counteract stockpiling. The approach varies widely across the region: countries such as Germany and France have introduced strict limits, while others, such as the UK and Ireland, have not ordered official restrictions. HBW Insight presents an analysis of the actions taken by 14 European countries to the upsurge in demand for OTCs.
Reckitt Benckiser has seen an unprecedented increase in demand for its OTCs since the COVID-19 outbreak and is urging Australian consumers to stop panic buying so its partners can restock stores.
As the coronavirus continues to spread across Europe, HBW Insight editors Tom Gallen and David Ridley discuss how the pandemic is impacting the region's consumer healthcare market.
Hypera is offloading a basket of brands it recently acquired from Takeda which are sold primarily in Mexico to São Paulo-based Eurofarma.
Teva's Ratiopharm and Italy's Recordati have submitted applications to switch drugs from prescription-to-OTC status through EMA's centralised procedure. Given only four products have been switched centrally to date, a double reclassification would be unprecedented.